Chorea and its disorders

Neurologic Clinics

Volumn 19, Issue 3, 2001, Pages 707-722

  Higgins Jr , Donald S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; LEVODOPA; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; REMACEMIDE; UBIQUINONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BASAL GANGLION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG TOLERABILITY; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; HUNTINGTON CHOREA; HYPERTHYROIDISM; PHYSICAL EXAMINATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT PLANNING; WILSON DISEASE;

EID: 0034838797     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(05)70041-4     Document Type: Article

References (96)

1. Long-term treatment effects of vitamin E for tardive dyskinesia
2. The pathophysiology of chorea/ballism and parkinsonism
3. Chorea and dystonia: A remote effect of carcinoma
4. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease
5. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity-akinesia
6. The functional anatomy of basal ganglia disorders
7. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington's disease
8. Huntington's disease progression: PET and clinical observations
9. 11C] raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length
10. 2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
11. Guidelines for the molecular genetic predictive test in Huntington's disease
12. Longitudinal change in basal ganglia volume in patients with Huntington's disease
13. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation
14. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes
15. Rigid and akinetic forms of Huntington's chorea
16. Wilson's disease
17. The likelihood of being affected with Huntington's disease by a particular age, for a specific CAG size
18. Psychiatric syndromes in Huntington's disease
19. Persistent Sydenham's chorea
20. Huntington disease: Genetics and epidemiology
21. Degeneration of pyramidal projection neurons in Huntington's disease cortex
22. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease
23. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
24. The spectrum of levodopa-induced dyskinesias
25. 10 tolerability in Huntington's Disease
26. Treatment of Huntington's disease and other choreic disorders
27. Diagnostic tests for choreoanthocytosis
28. Morphologic and histochemical characteristics of a spared subset of neruons in Huntington's disease
29. Differences in duration of Huntington's disease based on age at onset
30. Benign hereditary chorea improved on stimulant therapy
31. Hyperkinetic movement disorders during and after acute stroke: The Lausanne Stroke Registry
32. A dutch family with benign hereditary chorea of early onset: Differentiation from Huntington's disease
33. Etiology, pathology and treatment of chorea in the nineteenth century
34. Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington's disease
35. Successful treatment of rheumatic chorea with carbamazepine
36. The epidemiology of Huntington's disease
37. Single photon emission computed tomographic blood flow and magnetic resonance imaging of basal ganglia in Huntington's disease
38. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease
39. Early loss of neostriatal striosome neurons in Huntington's disease
40. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease
41. Paroxysmal kinesigenic choreoathetosis: A report of 26 patients
42. On chorea
43. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
44. Differential diagnosis of choreiform tardive dyskinesia
45. Muscle CT scan findings in McLeod syndrome and chorea-acanthocytosis
46. Tardive syndromes and other drug-induced movement disorders
47. 1H NMR spectroscopy
48. The diversity of neurologic events in systemic lupus erythematosus: Prospective clinical and computed tomographic classification of 82 events in 71 patients
49. Dentatorubral-pallidoluysian atrophy or Naito-Oyanagi disease
50. A controlled trial of remacemide hydrochloride in Huntington's disease
51. Progression of symptoms in the early and middle stages of Huntington's disease
52. Unstable exapansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA)
53. Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: Trophic and tropic effects in a rodent model of Huntington's disease
54. 10
55. Hemichorea and hemiballism associated with contralateral hemiparesis and ipsilateral basal ganglia lesions
56. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease
57. Huntington's disease mortality in the United States
58. Antiphospholipid antibodies
59. n repeat, in Huntington's disease
60. Psychological impact of genetic testing for Huntington's disease: An update of the literature
61. A comparison of the frequency of major affective disorder in Huntington's diease and Alzheimer's disease
62. Genetic testing of children at risk for Huntington's chorea
63. Chorea disclosing deterioration of polycythaemia vera
64. Movement disorders in pregnancy
65. Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol
66. Functional anatomy of the basal ganglia. I. The cortico-basal gangliathalamo-cortical loop
67. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry
68. Issues related to DNA testing for Huntington's disease in symptomatic patients
69. Chorea in patients with AIDS
70. N repeats in parent offspring pairs with Huntington's disease
71. Differential loss of striatal projection neurons in Huntington's disease
72. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients
73. The neuropathological features of neuroacanthocytosis
74. Neuropsychiatry of Huntington's disease and other basal ganglia disorders
75. Huntington's disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA)
76. Chorea-acanthocytosis: Genetic linkage to chromosome 9q21
77. Clinical and electroencephalographic findings in juvenile type DRPLA
78. Clinical correlation of striatal 1H MRS changes in Huntington's disease
79. Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photon-emission computed tomography
80. Increased rate of suicide among patients with Huntington's disease
81. Benign hereditary chorea: Entity or syndrome?
82. Huntington's disease: Cognitive and psychiatric features
83. On chorea
84. Juvenile Huntington's disease in the Netherlands
85. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease
86. Clinical assessment of 31 patients with Wilson's disease: Correlations with structural changes on magnetic resonance imaging
87. Chorea resulting from paraneoplastic striatal encephalitis
88. 2 receptor binding in patients with Huntington's disease and other choreas: A PET study
89. Clozapine versus placebo in Huntington's disease: A double blind randomised comparative study
90. Neuropathological classification of Huntington's disease
91. Wilson's disease
92. Protein aggregation and pathogenesis of Huntington's disease: Mechanisms and correlations
93. Hyperthyroidism presenting as recurrent short paroxysmal kinesigenic dyskinesia
94. PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline
95. Huntington's disease in Venezuela: Neurologic features and functional decline
96. Locus coeruleus involvement in Huntington's disease